MetaDAO has confirmed the Ranger redemption amount, with each token valued at approximately $0.822318.
Foresight News reported that MetaDAO tweeted it has confirmed the number of Ranger tokens to be redeemed, with the total eligible token amount being 6,137,825.101. The redemption wallet balance is $5,047,249.68, making each token worth approximately $0.822318. In addition, the official announcement excluded 247 accounts that did not meet the eligibility criteria, including 151 inactive/zero balance/project-owned accounts, 1 exchange wallet, and 95 Streamflow vests.
Previously, Foresight News reported that MetaDAO tweeted the RNGR liquidation snapshot was taken at 7:00 AM (UTC+8) on March 13. If users had deposited RNGR tokens in CEX or DeFi applications, it is recommended to withdraw them to their wallets so they can be included in the snapshot. The liquidation portal will go live on the MetaDAO website at 2:00 AM (UTC+8) on March 17.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
